KR20210145238A - 염증성 질환의 치료를 위한 신규 화합물 및 그의 약학 조성물 - Google Patents

염증성 질환의 치료를 위한 신규 화합물 및 그의 약학 조성물 Download PDF

Info

Publication number
KR20210145238A
KR20210145238A KR1020217035254A KR20217035254A KR20210145238A KR 20210145238 A KR20210145238 A KR 20210145238A KR 1020217035254 A KR1020217035254 A KR 1020217035254A KR 20217035254 A KR20217035254 A KR 20217035254A KR 20210145238 A KR20210145238 A KR 20210145238A
Authority
KR
South Korea
Prior art keywords
independently selected
substituted
compound
mixture
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217035254A
Other languages
English (en)
Korean (ko)
Inventor
오스카 만모리티
헬렌 마리 자리
미스라브 올서릭
데나나 블반
마리자나 코막
레지널드 크리스토퍼 사비에르 브리시
라리드 아카리
Original Assignee
갈라파고스 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈라파고스 엔.브이. filed Critical 갈라파고스 엔.브이.
Publication of KR20210145238A publication Critical patent/KR20210145238A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217035254A 2019-03-29 2020-03-24 염증성 질환의 치료를 위한 신규 화합물 및 그의 약학 조성물 Ceased KR20210145238A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1904373.6 2019-03-29
GBGB1904373.6A GB201904373D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2020/058064 WO2020200900A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
KR20210145238A true KR20210145238A (ko) 2021-12-01

Family

ID=66442982

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217035254A Ceased KR20210145238A (ko) 2019-03-29 2020-03-24 염증성 질환의 치료를 위한 신규 화합물 및 그의 약학 조성물

Country Status (18)

Country Link
US (1) US20220218679A1 (https=)
EP (1) EP3947378B1 (https=)
JP (1) JP2022526364A (https=)
KR (1) KR20210145238A (https=)
CN (1) CN113646305A (https=)
AR (1) AR118521A1 (https=)
AU (1) AU2020252038A1 (https=)
BR (1) BR112021019055A2 (https=)
CA (1) CA3134736A1 (https=)
CO (1) CO2021014223A2 (https=)
GB (1) GB201904373D0 (https=)
IL (1) IL286677A (https=)
MA (1) MA55497A (https=)
MX (1) MX2021011576A (https=)
PH (1) PH12021552375A1 (https=)
SG (1) SG11202110644WA (https=)
TW (1) TW202102501A (https=)
WO (1) WO2020200900A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
CN113243338A (zh) * 2021-05-14 2021-08-13 福州大学 一种小鼠缺血性卒中模型的构建与评估方法
EP4434981A4 (en) * 2021-12-23 2025-08-20 Hangzhou Polymed Biopharmaceuticals Inc FIVE- AND SIX-MEMBERED COMPOUND, ITS PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION AND ITS USE
WO2024133560A1 (en) * 2022-12-21 2024-06-27 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
EP4389747A1 (en) * 2022-12-21 2024-06-26 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
CN119751445B (zh) * 2024-12-10 2025-11-25 江南大学 6-乙炔基吡唑并[1,5-a]吡啶的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1657242A4 (en) * 2003-08-15 2008-10-29 Banyu Pharma Co Ltd imidazopyridine
JPWO2005108399A1 (ja) * 2004-05-10 2008-03-21 萬有製薬株式会社 イミダゾピリジン化合物
US9169260B2 (en) * 2011-03-22 2015-10-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP2018524372A (ja) * 2015-07-15 2018-08-30 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物
GB201518456D0 (en) * 2015-10-19 2015-12-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
WO2018060174A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN109890829B (zh) * 2016-11-02 2022-07-15 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
MA54755A (fr) * 2019-01-18 2021-11-24 Biogen Ma Inc Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
EP3947378B1 (en) 2024-11-13
MX2021011576A (es) 2021-10-13
CN113646305A (zh) 2021-11-12
SG11202110644WA (en) 2021-10-28
TW202102501A (zh) 2021-01-16
CO2021014223A2 (es) 2021-11-19
CA3134736A1 (en) 2020-10-08
IL286677A (en) 2021-10-31
MA55497A (fr) 2022-02-09
WO2020200900A1 (en) 2020-10-08
JP2022526364A (ja) 2022-05-24
GB201904373D0 (en) 2019-05-15
EP3947378A1 (en) 2022-02-09
US20220218679A1 (en) 2022-07-14
AR118521A1 (es) 2021-10-20
PH12021552375A1 (en) 2022-09-19
AU2020252038A1 (en) 2021-11-25
BR112021019055A2 (pt) 2021-11-30

Similar Documents

Publication Publication Date Title
EP3947378B1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
KR102720958B1 (ko) 질병의 치료를 위한 신규 화합물 및 그의 약학 조성물
CN113924146B (zh) 用于治疗疾病的新化合物及其药物组合物
KR20210143905A (ko) 염증성 질환의 치료를 위한 신규 화합물 및 그의 약학 조성물
EP3365341B1 (en) 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
KR20210143904A (ko) 염증성 질환의 치료를 위한 신규 화합물 및 그의 약학 조성물
TWI895846B (zh) 作為cGAS 抑制劑之環狀吡啶衍生物
KR20190117672A (ko) Ｉｒａｋ 및 ｊａｋ 억제제를 포함하는 항염 조성물
KR20160104730A (ko) 벤즈이미다졸 유도체 및 염증 질환의 치료를 위한 그의 약학 조성물
HK1177743A (en) Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20211028

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20230320

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250310

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250523

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D